First Drug For Postpartum Depression Gets FDA Nod

(RTTNews) - Postpartum depression, or PPD, is a mood disorder that can affect women after childbirth. In the U.s., estimates of new mothers identified with PPD each year vary by state from eitht to 20/%, with an overall average of 11.5%.

The first drug for women suffering from postpartum depression was approved on March 19. The drug Zulresso, developed by Sage Therapeutics, is administered as a continuous IV infusion for 60 hours.

The company plans to price the drug between $20,000 to $35,000 per course of treatment.

Zulresso comes with a boxed warning of sudden loss of consciousness, and a health care provider in a certified health care facility should be present while administering the drug.

Now, let's take a look at the new drug approvals of February.